Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China · Delayed Price · Currency is CNY 21.89
-0.48 (-2.15%)
At close: Sep 11, 2026
SHA:688443 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 338.42 | 230.7 | 30.07 | 1.07 | 0.48 | - |
Other Revenue | 0.01 | 0.03 | 0.03 | 0.15 | - | 39.19 |
| 338.44 | 230.73 | 30.09 | 1.21 | 0.48 | 39.19 | |
Revenue Growth | 348.41% | 666.66% | 2384.11% | 154.92% | -98.79% | 3502.99% |
Cost of Revenue | 23.85 | 16.59 | 5.92 | -0.24 | 1.77 | 19.67 |
Gross Profit | 314.58 | 214.14 | 24.17 | 1.45 | -1.3 | 19.52 |
Selling, General & Admin | 384.92 | 319 | 252.49 | 173.79 | 153.62 | 24.22 |
Research & Development | 495.39 | 472.83 | 609.79 | 620.4 | 454.49 | 295.32 |
Other Operating Expenses | 23.51 | 4.94 | 3.27 | 2.56 | 1.3 | 1.84 |
Operating Expenses | 903.98 | 797.25 | 866.19 | 796.74 | 609.42 | 321.34 |
Operating Income | -589.4 | -583.11 | -842.02 | -795.29 | -610.72 | -301.82 |
Interest Expense | -16.31 | -31.41 | -28.9 | -34.99 | -32.75 | -32.42 |
Interest & Investment Income | 24.8 | 44.7 | 66.75 | 17.46 | 0.88 | 0.43 |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | - | -0.1 | -0.8 | 0.24 |
Other Non Operating Income (Expenses) | -12.74 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 |
EBT Excluding Unusual Items | -593.63 | -569.82 | -804.18 | -812.94 | -643.39 | -333.59 |
Gain (Loss) on Sale of Investments | 4.44 | 4.44 | 2.58 | 1.94 | 7.14 | 4.11 |
Gain (Loss) on Sale of Assets | -4.89 | -4.9 | -0.54 | -0 | -0 | - |
Asset Writedown | -2.2 | - | - | - | - | -0.43 |
Other Unusual Items | 33.76 | 34.62 | 4.86 | 9.68 | 59.89 | 7.78 |
Pretax Income | -562.52 | -535.65 | -797.27 | -801.32 | -576.37 | -322.13 |
Net Income | -562.52 | -535.65 | -797.27 | -801.32 | -576.37 | -322.13 |
Net Income to Common | -562.52 | -535.65 | -797.27 | -801.32 | -576.37 | -322.13 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 368 | 367 | 367 | 321 | 274 | 275 |
Shares Outstanding (Diluted) | 368 | 367 | 367 | 321 | 274 | 275 |
Shares Change | -0.03% | -0.14% | 14.63% | 16.79% | -0.32% | - |
EPS (Basic) | -1.53 | -1.46 | -2.17 | -2.50 | -2.10 | -1.17 |
EPS (Diluted) | -1.53 | -1.46 | -2.17 | -2.50 | -2.10 | -1.17 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -687.51 | -423.33 | -620.75 | -468.56 | -323.85 | -350.52 |
Free Cash Flow Per Share | -1.87 | -1.15 | -1.69 | -1.46 | -1.18 | -1.27 |
Gross Margin | 92.95% | 92.81% | 80.32% | 119.44% | -273.11% | 49.80% |
Operating Margin | -174.15% | -252.73% | -2797.87% | -65645.33% | -128506.77% | -770.14% |
Profit Margin | -166.21% | -232.16% | -2649.19% | -66142.68% | -121278.86% | -821.97% |
Free Cash Flow Margin | -203.14% | -183.48% | -2062.65% | -38675.98% | -68143.75% | -894.41% |
EBITDA | -530.07 | -525.97 | -783.9 | -746.46 | -570.86 | -270.57 |
EBITDA Margin | -156.62% | -227.96% | - | - | - | - |
D&A For EBITDA | 59.33 | 57.13 | 58.12 | 48.84 | 39.86 | 31.26 |
EBIT | -589.4 | -583.11 | -842.02 | -795.29 | -610.72 | -301.82 |
EBIT Margin | -174.15% | -252.73% | - | - | - | - |
Revenue as Reported | 185.34 | 230.73 | 30.09 | 1.21 | 0.48 | 39.19 |
Advertising Expenses | - | 1.8 | 2.34 | 0.35 | - | - |